<?xml version='1.0' encoding='utf-8'?>
<document id="22813462"><sentence text="Deep understanding of the interaction between thienorphine and UDP-glucuronosyltransferase (UGT) isoforms."><entity charOffset="46-58" id="DDI-PubMed.22813462.s1.e0" text="thienorphine" /></sentence><sentence text="Thienorphine has been demonstrated to be a potent, long-acting partial opioid agonist"><entity charOffset="0-12" id="DDI-PubMed.22813462.s2.e0" text="Thienorphine" /></sentence><sentence text=" It is being developed as a good candidate to treat opioid dependence" /><sentence text="        The thienorphine's glucuronide was detected after thienorphine was incubated with human liver microsomes (HLMs)"><entity charOffset="58-70" id="DDI-PubMed.22813462.s4.e0" text="thienorphine" /></sentence><sentence text=" Recombinant UGT isoforms screening experiment and enzyme kinetic study showed that UGT1A1 completely contributed to the glucuronidation of thienorphine"><entity charOffset="140-152" id="DDI-PubMed.22813462.s5.e0" text="thienorphine" /></sentence><sentence text="        Among the tested UGT isoforms, UGT1A3 and UGT2B7 were inhibited by thienorphine, with other UGT isoforms negligibly influenced"><entity charOffset="75-87" id="DDI-PubMed.22813462.s6.e0" text="thienorphine" /></sentence><sentence text=" The inhibition type is competitive, and inhibition kinetic parameters (K(i)) were 1" /><sentence text="65 and 5" /><sentence text="27 Î¼M for UGT1A3 and UGT2B7, respectively" /><sentence text=" However, due to low plasma concentration of thienorphine, in vivo drug-drug interaction might not occur"><entity charOffset="45-57" id="DDI-PubMed.22813462.s10.e0" text="thienorphine" /></sentence><sentence text="" /></document>